Navigation Links
Xoft Introduces Electronic Brachytherapy Cancer Treatment Platform at ESTRO Meeting
Date:9/13/2010

BARCELONA, Spain, Sept. 13 /PRNewswire/ -- Xoft, Inc., the pioneer of localized, isotope-free radiation treatment delivered in minimally-shielded clinical settings, today announced the introduction of the Axxent® Electronic Brachytherapy, eBx™ System to physicians and distributors in Europe.  The Axxent eBx System, which delivers treatment directly to cancer sites with minimal radiation exposure to surrounding healthy tissue, treats breast, endometrial and skin cancers and Intraoperative Radiation Therapy (IORT) indications.  The announcement was made here at the 29th Annual Meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO), where Xoft is exhibiting for the first time.

Xoft recently received CE Mark Approval for the Axxent Electronic Brachytherapy System and treatment applicators, which permits sales and marketing of the System throughout the European Union. Originally FDA-cleared for the treatment of early stage breast cancer, the Axxent eBx Systems has received supplemental clearances for additional indications and for intraoperative use.  

"With major IORT and other radiation therapy studies having been conducted in Europe over the past several years, the market is primed for launch of Electronic Brachytherapy," said Rob Kirby, Xoft's Vice President of Business Development. "We are excited to formally introduce the Axxent System to European radiation oncologists at ESTRO, and we will also use the meeting to build strong distribution relationships to drive adoption throughout the EU."  

The clinical benefits of isotope-free, 50 kV radiation therapy continue to be substantiated by multiple publications.  The most recent include publication of four-year data from the TARGIT-A (Targeted Intraoperative Radiation Therapy) multicenter clinical trial, and recent Xoft clinical publications on APBI, endometrial cancer and breast IORT.  

As a platform technology, the Axxent System is designed to deliver localized, isotope-free radiation treatment in minimally-shielded clinical settings under the supervision of a radiation oncologist to help reduce recurrence of cancer and improve survival. Utilizing a proprietary miniaturized X-ray source and mobile controller, treatment can be performed without the need for a shielded room, allowing radiation oncologists and medical personnel to be present during treatment, which minimizes patient anxiety.

"With minimal exposure to healthy tissues and rapid dose fall-off that enables treatment in minimally-shielded settings, Electronic Brachytherapy delivers targeted treatment that is professionally validated and patient friendly," said Michael Klein, President and CEO of Xoft.  "Building on years of clinical experience and scientific validation since eBx was first introduced as an X-ray-based, electronic treatment option for early stage breast cancer, we are very pleased to offer this important oncology treatment platform to radiation oncologists and patients in Europe.  Delivering safe, targeted treatment for breast, endometrial, skin and other cancers, we expect eBx will continue to increase access to critical treatment as well as improve compliance and patient care."

About Xoft, Inc.

Xoft develops Electronic Brachytherapy (eBx) systems based upon miniaturized X-ray tube technology for the practice of radiation oncology in virtually any clinical setting, eliminating the need for heavily shielded environments. The Axxent® treatment platform provides a therapeutic dose of radiation directly to the region at risk with minimal radiation exposure to surrounding healthy tissue and without the logistics and costs associated with using radioactive isotopes.  FDA-cleared for treatment of early stage breast cancer, skin cancer and endometrial cancer, the Axxent System is also cleared for use in the treatment of other cancers or conditions where radiation therapy is indicated. For information, visit www.xoftinc.com.

Axxent is a registered trademark and eBx is a trademark of Xoft, Inc.


'/>"/>
SOURCE Xoft, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Open House at Gulf Coast Cancer Treatment Center Introduces Elekta Synergy® to Community
2. Laerdal Introduces SimMan Essential
3. Elsevier Introduces SciVerse, an Innovative Platform for Accelerating Science
4. UPDATE: China PharmaHub Corp. Introduces a Magic Bullet Liver Cancer Therapy to China, Hong Kong, Taiwan, Macau, Singapore, Malaysia, and Bangladesh
5. China PharmaHub Corp. Introduces a Magic Bullet Liver Cancer Therapy to China, Hong Kong, Taiwan, Macau, Singapore, Malaysia, and Bangladesh
6. Medical Website Design Experts Aurora Information Technology Introduces Its Newest Website Launch, Muscat Eye Laser Center
7. PAREXEL Introduces Temperature Recording Solution for Study Drug Transportation, Bringing More Efficiency to Clinical Supply Chain
8. Block Engineering Introduces Family of Quantum Cascade Laser Mid-IR Spectrometers
9. Instrumentation Laboratory Introduces Fully Automated, Liquid, Ready-to-Use HemosIL® HIT-Ab(PF4-H) Assay in Europe
10. Omnicell Introduces New Omnicell Packager With WorkflowRx Software for Improved Pharmacy Efficiency
11. RoboticOncology.com: Robotic Surgeon Dr. David Samadi, MD Introduces His SMART Surgery Technique for Prostate Cancer Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Summary Breast ... cancer and the most common cancer in women worldwide, ... disease exceedingly prevalent. The number of women diagnosed with ... but the number of deaths has declined due to ... treatment has been revolutionized in the past four decades, ...
(Date:2/4/2016)... VIEW, Calif., Feb. 4, 2016  Omnicell, Inc. (NASDAQ: ... management solutions to healthcare systems, today announced results for ... --> --> GAAP ... $130.3 million, up $5.1 million or 4.1% from the ... 7.2% from the fourth quarter of 2014. Revenue for ...
(Date:2/4/2016)... 4, 2016 In response to the opioid abuse ... Commissioner for Medical Products and Tobacco, along with other FDA ... agency,s approach to opioid medications. The plan will focus on ... in pain access to effective relief. ... , Re-examine the risk-benefit paradigm for opioids and ensure that ...
Breaking Medicine Technology:
(Date:2/8/2016)... Los Angeles, CA (PRWEB) , ... February 08, 2016 , ... ... autism conference held annually in this country. The AutismOne 2016 Conference, which is being ... the truth they often won’t hear elsewhere about helpful interventions and causes of chronic ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... MyDecision™ empowers employers and organizations with the tools and information to lower the ... elements to cut the cost of providing employee healthcare benefits by as much ...
(Date:2/6/2016)... ... February 06, 2016 , ... With the FCPX LUT: Summer ... grades to their footage. A LUT is a Lookup Table that contains a mathematical ... color indicated by the table. By manipulating each pixel, LUT's can change each color ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the air at King Kullen! ... assortments and packaging. This staple for Valentine’s Day is a must-have, and can be ... Valentine’s Day, not only are long-stem roses available, but also other flower bouquets, elegantly ...
(Date:2/5/2016)... ... 2016 , ... The event is being held on April 7, 2016 from ... Triumph Over Parkinson’s will fund nearly $100,000 for research for the care and cure ... disease and is the architect of this informative event to raise awareness and funds ...
Breaking Medicine News(10 mins):